-$0.89 EPS Expected for Repare Therapeutics Inc. (NASDAQ:RPTX) This Quarter

Equities analysts predict that Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) will post earnings per share of ($0.89) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Repare Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($1.00). Repare Therapeutics reported earnings of ($0.58) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 53.4%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Repare Therapeutics will report full year earnings of ($3.59) per share for the current financial year, with EPS estimates ranging from ($4.25) to ($2.92). For the next fiscal year, analysts forecast that the company will post earnings of ($3.91) per share, with EPS estimates ranging from ($4.21) to ($3.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Repare Therapeutics.

Repare Therapeutics (NASDAQ:RPTX – Get Rating) last issued its earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative net margin of 1,406.68% and a negative return on equity of 41.95%. The business had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $3.54 million.

Several research analysts have recently weighed in on the stock. Stifel Nicolaus cut shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Repare Therapeutics in a report on Tuesday, April 12th. The Goldman Sachs Group started coverage on shares of Repare Therapeutics in a report on Thursday, March 17th. They set a “buy” rating and a $43.00 target price for the company. Zacks Investment Research cut shares of Repare Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 5th. Finally, Piper Sandler reduced their target price on shares of Repare Therapeutics from $40.00 to $25.00 in a report on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Shares of RPTX traded down $0.07 during mid-day trading on Friday, hitting $11.68. 142,733 shares of the company traded hands, compared to its average volume of 177,352. The stock has a 50-day moving average price of $13.65 and a two-hundred day moving average price of $18.42. Repare Therapeutics has a 1 year low of $9.59 and a 1 year high of $35.75. The stock has a market cap of $489.11 million, a price-to-earnings ratio of -4.14 and a beta of 0.60.

Large investors have recently modified their holdings of the stock. National Bank of Canada FI bought a new position in shares of Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc raised its stake in Repare Therapeutics by 55.5% during the fourth quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock valued at $83,000 after purchasing an additional 1,400 shares in the last quarter. California State Teachers Retirement System purchased a new stake in Repare Therapeutics during the third quarter valued at $198,000. Virtus ETF Advisers LLC raised its stake in Repare Therapeutics by 28.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after purchasing an additional 1,873 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Repare Therapeutics by 17.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,578 shares of the company’s stock valued at $231,000 after purchasing an additional 1,599 shares in the last quarter. Hedge funds and other institutional investors own 69.41% of the company’s stock.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Further Reading